Interleukin-32 in Infection, Inflammation and Cancer Biology
References
- 1. Zuber Shaikh P. Cytokines & their physiologic and pharmacologic functions in inflammation: A review. Int J Pharm Life Sci. 2011;2(11):1247–63.
- 2. Dinarello C a. Historical Review of Cytokines. Eur J Immunol. 2007;37(Suppl 1):S34–45.
- 3. Akdis M, Aab A, Altunbulakli C, Azkur K, Costa RA, Crameri R, et al. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor beta, and TNF-alpha: Receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2016 Aug;
- 4. Soufli I, Toumi R, Rafa H, Touil-Boukoffa C. Overview of cytokines and nitric oxide involvement in immuno-pathogenesis of inflammatory bowel diseases. World J Gastrointest Pharmacol Ther. 2016 Aug;7(3):353–60.
- 5. Ah L. Abbas AK, Lichtman Ah, Pober JS. Cellular and Molecular Immunology, 4. 2001. p. 1–22.
- 6. Lin W, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Investig. 2007;117(5):1175–83.
- 7. Atretkhany K-SN, Drutskaya MS, Nedospasov SA, Grivennikov SI, Kuprash D V. Chemokines, cytokines and exosomes help tumors to shape inflammatory microenvironment. Pharmacol Ther. 2016 Sep;
- 8. Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers (Basel). 2011;3(4):3856–93.
- 9. Heinhuis B, Netea MG, van den Berg WB, Dinarello CA, Joosten LAB. Interleukin-32: a predominantly intracellular proinflammatory mediator that controls cell activation and cell death. Cytokine. 2012 Nov;60(2):321–7.
- 10. Dinarello C a, Kim S-H. IL-32, a novel cytokine with a possible role in disease. Ann Rheum Dis [Internet]. 2006;65 Suppl 3(May 2008):iii61-4.
- 11. Dahl CA, Schall RP, He HL, Cairns JS. Identification of a novel gene expressed in activated natural killer cells and T cells. J Immunol. 1992 Jan;148(2):597–603.
- 12. Kang J-W, Park YS, Lee DH, Kim MS, Bak Y, Ham SY, et al. Interaction network mapping among IL-32 iso-forms. Biochimie. 2014 Jun;101:248–51.
- 13. Jaekal J, Jhun H, Hong J, Park S, Lee J, Yoon D, et al. Cloning and characterization of bovine interleukin-32 beta isoform. Vet Immunol Immunopathol. 2010 Sep;137(1–2):166–71.
- 14. Lee S, Kim S, Bae S, Choi J, Hong J, Ryoo S, et al. Interleukin-32 gamma specific monoclonal antibody and developing IL-32 specific ELISA. Hybridoma (Larchmt). 2010;29(6):501–9.
- 15. Heinhuis B, Koenders MI, van den Berg WB, Netea MG, Dinarello CA, Joosten LAB. Interleukin 32 (IL-32) contains a typical alpha-helix bundle structure that resembles focal adhesion targeting region of focal adhesion kinase-1. J Biol Chem. 2012 Feb;287(8):5733–43.
- 16. Netea MG, Azam T, Ferwerda G, Girardin SE, Walsh M, Park J-S, et al. IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci U S A [Internet]. 2005;102(45):16309–14.
- 17. Monteleone K, Di Maio P, Cacciotti G, Falasca F, Fraulo M, Falciano M, et al. Interleukin-32 isoforms: expression, interaction with interferon-regulated genes and clinical significance in chronically HIV-1-infected patients. Med Microbiol Immunol. 2014 Jun;203(3):207–16.
- 18. Heinhuis B, Plantinga TS, Semango G, Kusters B, Netea MG, Dinarello CA, et al. Alternatively spliced isoforms of IL-32 differentially influence cell death pathways in cancer cell lines. Carcinogenesis. 2016 Feb;37(2):197–205.
- 19. Alternatively Spliced Isoforms of Tissue Factor Pathway Inhibitor.
- 20. Nold-Petry C a, Nold MF, Zepp J a, Kim S-H, Voelkel NF, Dinarello C a. IL-32-dependent effects of IL-1beta on endothelial cell functions. Proc Natl Acad Sci U S A [Internet]. 2009;106(10):3883–8.
- 21. El-Far M, Kouassi P, Sylla M, Zhang Y, Fouda A, Fabre T, et al. Proinflammatory isoforms of IL-32 as novel and robust biomarkers for control failure in HIV-infected slow progressors. Sci Rep. 2016;6:22902.
- 22. Kim S, Lee S, Her E, Bae S, Choi J, Hong J, et al. Protein-ase 3-processed form of the recombinant IL-32 separate domain. BMB Rep [Internet]. 2008;41(11):814–9.
- 23. Park G Bin, Hur DY, Kim YS, Lee HK, Yang JW, Kim D. TLR3/TRIF signalling pathway regulates IL-32 and IFN-β secretion through activation of RIP-1 and TRAF in the human cornea. Vol. 19, Journal of Cellular and Molecular Medicine. 2015. p. 1042–54.
- 24. Nakayama M, Niki Y, Kawasaki T, Takeda Y, Ikegami H, Toyama Y, et al. IL-32-PAR2 axis is an innate immunity sensor providing alternative signaling for LPS-TRIF axis. Sci Rep. 2013;3:2960.
- 25. Hong J, Bae S, Kang Y, Yoon D, Bai X, Chan ED, et al. Suppressing IL-32 in monocytes impairs the induction of the proinflammatory cytokines TNFα and IL-1β. Cytokine. 2010;49(2):171–6.
- 26. Escamilla-Tilch M, Filio-Rodriguez G, Garcia-Rocha R, Mancilla-Herrera I, Mitchison NA, Ruiz-Pacheco JA, et al. The interplay between pathogen-associated and danger-associated molecular patterns: an inflammatory code in cancer? Immunol Cell Biol. 2013;91(10):601–10.
- 27. Rajamuthiah R, Mylonakis E. Effector triggered immunity. Virulence. 2014;5(7):697–702.
- 28. Nakayama M, Niki Y, Kawasaki T, Takeda Y, Ikegami H, Toyama Y, et al. IL-32-PAR2 axis is an innate immunity sensor providing alternative signaling for LPS-TRIF axis. [Internet]. Vol. 3, Scientific reports. 2013. p. 2960.
- 29. Oh JH, Cho M-C, Kim J-H, Lee SY, Kim HJ, Park ES, et al. IL-32γ inhibits cancer cell growth through inactivation of NF-κB and STAT3 signals. [Internet]. Onco-gene. 2011. p. 1–15.
- 30. Joosten LAB, Heinhuis B, Netea MG, Dinarello CA. Novel insights into the biology of interleukin-32. Vol. 70, Cellular and Molecular Life Sciences. 2013. p. 3883–92.
- 31. Novick D, Rubinstein M, Azam T, Rabinkov A, Dinarello CA, Kim S-H. Proteinase 3 is an IL-32 binding protein. Proc Natl Acad Sci U S A [Internet]. 2006;103(9):3316–21.
- 32. Nold-Petry CA, Rudloff I, Baumer Y, Ruvo M, Marasco D, Botti P, et al. IL-32 promotes angiogenesis. J Immunol [Internet]. 2014;192(2):589–602.
- 33. Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol. 2005 Jan;6(1):56–68.
- 34. Schaller MD. FAK and paxillin: regulators of N-cadherin adhesion and inhibitors of cell migration? J Cell Biol. 2004 Jul;166(2):157–9.
- 35. Yano H, Mazaki Y, Kurokawa K, Hanks SK, Matsuda M, Sabe H. Roles played by a subset of integrin signaling molecules in cadherin-based cell-cell adhesion. J Cell Biol. 2004 Jul;166(2):283–95.
- 36. Goda C, Kanaji T, Kanaji S, Tanaka G, Arima K, Ohno S, et al. Involvement of IL-32 in activation-induced cell death in T cells. Int Immunol. 2006;18(2):233–40.
- 37. Hasegawa H, Thomas HJ, Schooley K, Born TL. Native IL-32 is released from intestinal epithelial cells via a non-classical secretory pathway as a membrane-associated protein. Cytokine. 2011 Jan;53(1):74–83.
- 38. Bae S, Kang D, Hong J, Chung B, Choi J, Jhun H, et al. Characterizing antiviral mechanism of interleukin-32 and a circulating soluble isoform in viral infection. Cytokine. 2012 Apr;58(1):79–86.
- 39. Zepp J a, Nold-Petry C a, Dinarello C a, Nold MF. Protection from RNA and DNA viruses by IL-32. J Immunol [Internet]. 2011;186(7):4110–8.
- 40. Yang J, Jiang H, Chen S, Chen J, Xu S, Li W, et al. CBP knockdown inhibits angiotensin II-induced vascular smooth muscle cells proliferation through downregulating NF-kB transcriptional activity. Mol Cell Biochem. 2010 Jul;340(1–2):55–62.
- 41. Lee S, Kim J-H, Kim H, Kang JW, Kim S-H, Yang Y, et al. Activation of the interleukin-32 pro-inflammatory pathway in response to human papillomavirus infection and over-expression of interleukin-32 controls the expression of the human papillomavirus oncogene. Immunology. 2011 Mar;132(3):410–20.
- 42. Zhou Y, Zhu Y. Important Role of the IL-32 Inflammatory Network in the Host Response against Viral Infection. Viruses. 2015 Jun;7(6):3116–29.
- 43. Nold MF, Nold-Petry C a, Pott GB, Zepp J a, Saavedra MT, Kim S-H, et al. Endogenous IL-32 controls cytokine and HIV-1 production. J Immunol. 2008;181(1):557–65.
- 44. El-Far M, Kouassi P, Sylla M, Zhang Y, Fouda A, Fabre T, et al. Proinflammatory isoforms of IL-32 as novel and robust biomarkers for control failure in HIV-infected slow progressors. [Internet]. Vol. 6, Scientific reports. 2016. p. 22902.
- 45. Freeman ML, Shive CL, Nguyen TP, Younes S-A, Panigrahi S, Lederman MM. Cytokines and T-Cell Homeostasis in HIV Infection. J Infect Dis. 2016 Oct;214 Suppl:S51-7.
- 46. Xu Q, Pan X, Shu X, Cao H, Li X, Zhang K, et al. Increased interleukin-32 expression in chronic hepatitis B virus-infected liver. Vol. 65, Journal of Infection. 2012. p. 336–42.
- 47. Lai K-Y, Chou Y-C, Lin J-H, Liu Y, Lin K-M, Doong S-L, et al. Maintenance of Epstein-Barr Virus Latent Status by a Novel Mechanism, Latent Membrane Protein 1-Induced Interleukin-32, via the Protein Kinase Cdelta Pathway. J Virol. 2015 Jun;89(11):5968–80.
- 48. Zou Y, Bao J, Pan X, Lu Y, Liao S, Wang X, et al. NKP30-B7-H6 Interaction Aggravates Hepatocyte Damage through Up-Regulation of Interleukin-32 Expression in Hepatitis B Virus-Related Acute-On-Chronic Liver Failure. PLoS One. 2015;10(8):e0134568.
- 49. Bai X, Kim S-H, Azam T, McGibney MT, Huang H, Dinarello C a, et al. IL-32 is a host protective cytokine against Mycobacterium tuberculosis in differentiated THP-1 human macrophages. J Immunol. 2010;184(7):3830–40.
- 50. Felaco P, Castellani ML, De Lutiis MA, Felaco M, Pandolfi F, Salini V, et al. IL-32: A newly-discovered pro-inflammatory cytokine. Vol. 23, Journal of Biological Regulators and Homeostatic Agents. 2009. p. 141–7.
- 51. Netea MG, Azam T, Lewis EC, Joosten LAB, Wang M, Langenberg D, et al. Mycobacterium tuberculosis induces interleukin-32 production through a caspase-1/ IL-18/interferon-γ-dependent mechanism. PLoS Med. 2006;3(8):1310–9.
- 52. Montoya D, Inkeles MS, Liu PT, Realegeno S, Teles RMB, Vaidya P, et al. IL-32 is a molecular marker of a host defense network in human tuberculosis. [Internet]. Vol. 6, Science translational medicine. 2014. p. 250ra114.
- 53. Joosten LAB, Netea MG, Kim S-H, Yoon D-Y, Oppers-Walgreen B, Radstake TRD, et al. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci U S A [Internet]. 2006;103(9):3298–303.
- 54. Heinhuis B, Koenders MI, van de Loo FA, Netea MG, van den Berg WB, Joosten LAB. Inflammation-dependent secretion and splicing of IL-32{gamma} in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2011 Mar;108(12):4962–7.
- 55. Moon Y-M, Yoon B-Y, Her Y-M, Oh H-J, Lee J-S, Kim K-W, et al. IL-32 and IL-17 interact and have the potential to aggravate osteoclastogenesis in rheumatoid arthritis. Arthritis Res Ther [Internet]. 2012;14(6):R246.
- 56. Kim S. Interleukin-32 in inflammatory autoimmune diseases. Immune Netw [Internet]. 2014;14(3):123–7.
- 57. Lee E-J, Lee E-J, Chung Y-H, Song D-H, Hong S, Lee C-K, et al. High level of interleukin-32 gamma in the joint of ankylosing spondylitis is associated with osteo-blast differentiation. Arthritis Res Ther. 2015;17:350.
- 58. Ciccia F, Rizzo A, Accardo-Palumbo A, Giardina A, Bombardieri M, Guggino G, et al. Increased expression of interleukin-32 in the inflamed ileum of ankylosing spondylitis patients. Rheumatology (Oxford). 2012 Nov;51(11):1966–72.
- 59. Shioya M, Nishida A, Yagi Y, Ogawa A, Tsujikawa T, Kim-Mitsuyama S, et al. Epithelial overexpression of interleukin-32?? in inflammatory bowel disease. Clin Exp Immunol. 2007;149(3):480–6.
- 60. Khawar B, Abbasi MH, Sheikh N. A panoramic spectrum of complex interplay between the immune system and IL-32 during pathogenesis of various systemic infections and inflammation. [Internet]. Vol. 20, European journal of medical research. 2015. p. 7.
- 61. Calabrese F, Baraldo S, Bazzan E, Lunardi F, Rea F, Maestrelli P, et al. IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008 Nov;178(9):894–901.
- 62. Soyka MB, Treis A, Eiwegger T, Menz G, Zhang S, Holzmann D, et al. Regulation and expression of IL-32 in chronic rhinosinusitis. Allergy Eur J Allergy Clin Immunol. 2012;67(6):790–8.
- 63. Keswani A, Kern RC, Schleimer RP, Kato A. Role of interleukin-32 in chronic rhinosinusitis. Curr Opin Allergy Clin Immunol [Internet]. 2013;13(1):13–8.
- 64. Meyer N, Zimmermann M, Bürgler S, Bassin C, Woehrl S, Moritz K, et al. IL-32 is expressed by human primary keratinocytes and modulates keratinocyte apoptosis in atopic dermatitis. J Allergy Clin Immunol. 2010;125(4).
- 65. Hu L-J, Li L, Fitzpatrick JE, Francis SO, Fujita M, Takashi MK, et al. The Proinflammatory Cytokine Inter-leukin-32 is expressed in Keratinocytes and Dendritic Cells Obtained from Patients with Chronic Plaque Psoriasis (CPPs). J Immunol [Internet]. 2007;178(Meeting Abstracts):S165.
- 66. Heinhuis B, Popa CD, van Tits BLJH, Kim SH, Zeeuwen PL, van den Berg WB, et al. Towards a role of interleukin-32 in atherosclerosis. Cytokine. 2013;64(1):433–40.
- 67. Kim SJ, Lee S, Kwak A, Kim E, Jo S, Bae S, et al. Interleukin-32gamma transgenic mice resist LPS-mediated septic shock. J Microbiol Biotechnol. 2014 Aug;24(8):1133–42.
- 68. Ko NY, Mun SH, Lee SH, Kim JW, Kim DK, Kim HS, et al. Interleukin-32alpha production is regulated by MyD88-dependent and independent pathways in IL-1beta-stimulated human alveolar epithelial cells. Immunobiology. 2011;216(1–2):32–40.
- 69. Beury DW, Parker KH, Nyandjo M, Sinha P, Carter K a., Ostrand-Rosenberg S. Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors. J Leukoc Biol [Internet]. 2014;96(December):1109–18.
- 70. Zeng Q, Li S, Zhou Y, Ou W, Cai X, Zhang L, et al. Interleukin-32 contributes to invasion and metastasis of primary lung adenocarcinoma via NF-kappaB induced matrix metalloproteinases 2 and 9 expression. Vol. 65, Cytokine. 2014. p. 24–32.
- 71. Lee J, Kim KE, Cheon S, Song JH, Houh Y, Kim TS, et al. Interleukin-32alpha induces migration of human melanoma cells through downregulation of E-cadherin. Oncotarget. 2016 Aug;
- 72. Sakitani K, Hirata Y, Hayakawa Y, Serizawa T, Nakata W, Takahashi R, et al. Role of interleukin-32 in Helicobacter pylori-induced gastric inflammation. Infect Immun. 2012;80(11):3795–803.
- 73. Peng LS, Zhuang Y, Li WH, Zhou YY, Wang TT, Chen N, et al. Elevated Interleukin-32 expression is associated with Helicobacter pylori-related gastritis. Vol. 9, PLoS ONE. 2014.
- 74. Bak Y, Kwon T, Bak I, Hong J, Yu D. IL-32θ inhibits stemness and epithelial-mesenchymal transition of cancer stem cells via the STAT3 pathway in colon cancer. Vol. 7. 2016.
- 75. LEE H-J, LIANG ZHEL, HUANG SMEI, LIM J-S, YOON D-Y, LEE H-J, et al. Overexpression of IL-32 is a novel prognostic factor in patients with localized clear cell renal cell carcinoma. Oncol Lett [Internet]. 2012 Feb 2;3(2):490–6.
- 76. Kang YH, Park M-Y, Yoon D-Y, Han SR, Lee C Il, Ji NY, et al. Dysregulation of overexpressed IL-32alpha in hepatocellular carcinoma suppresses cell growth and induces apoptosis through inactivation of NF-kappaB and Bcl-2. Cancer Lett. 2012 May;318(2):226–33.
- 77. Chen J, Wang S, Su J, Chu G, You H, Chen Z, et al. Interleukin-32alpha inactivates JAK2/STAT3 signaling and reverses interleukin-6-induced epithelial-mesenchymal transition, invasion, and metastasis in pancreatic cancer cells. Onco Targets Ther. 2016;9:4225–37.
- 78. Yousif NG, Al-Amran FG, Hadi N, Lee J, Adrienne J. Expression of IL-32 modulates NF-kappaB and p38 MAP kinase pathways in human esophageal cancer. Cytokine. 2013 Jan;61(1):223–7.
- 79. Meyer N, Christoph J, Makrinioti H, Indermitte P, Rhyner C, Soyka M, et al. Inhibition of angiogenesis by IL-32: Possible role in asthma. J Allergy Clin Immunol. 2012;129(4).
Language: English
Page range: 75 - 82
Submitted on: Sep 20, 2016
Accepted on: Oct 26, 2016
Published on: Jun 5, 2020
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
Related subjects:
© 2020 Mladen Pavlovic, Ivan Jovanovic, Nebojsa Arsenijevic, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.